Skip to main content
SpringerLink
Log in

Cost-per-QALY League Tables

Their Role in Pharmacoeconomic Analysis

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

It has become common for analysts to present the findings of cost-utility analyses in cost per quality-adjusted life-year (QALY) league tables or rankings. These purport to s how the relative value-for-money of different healthcare technologies. Concomitantly, there is an increasing market for cost-effectiveness data worldwide.

However, the practice of constructing league tables has drawn criticism. Claims of inappropriate comparisons, and poor and flawed methodology have been made. How should decision-makers view cost/QALY league tables? In future, published league tables will need 10 be more informative and thus, by necessity, complex. The principal obstacle to informing health policy- makers with economic analysis is the lack of appropriate outcome data. From this follows uncertainty as to what represents acceptable value-for-money in healthcare purchasing. Thus, the long term objective must be to obtain valid assessments of the value of current and new health service activities. It is in this context that league tables may eventually be most helpful. More immediately, a strategy is required to help decision-makers to prioritise resources rationally with incomplete information.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized controlled trials. Medical Care 30: 231–243, 1992

    Article  PubMed  CAS  Google Scholar 

  • Birch S, DonaldsOn C. Applications of cost-benefit analysis to health care: departures from welfare economic theory. Journal of Health Economics 6: 211–225, 1987

    Article  PubMed  CAS  Google Scholar 

  • Birch S, Gafni A. Cost-effectiveness/utility analyses: do current decision rules lead us 10 where we want to be? Journal of Health Economics 11: 279–296, 1992

    Article  PubMed  CAS  Google Scholar 

  • Borowitz M, Sheldon T. Controlling health care: from economic incentives to micro-clinical regulation. Health Economics 2: 201–204, 1993

    Article  PubMed  CAS  Google Scholar 

  • Commonwealth of Australia. Guidelines for the submissions to the Pharmaceutical Benefits Advisory Committee: including economic analyses. Commonwealth of Australia, Woden, ACT, 1990

  • Congress of the United States Office of TechnOlogy Assessment. Evaluation of the Oregon Medicaid proposal: summary. US Government Printing Office, Washington, DC, 1992

  • Coulter A, Klassen A, MacKenzie IZ, McPherson K. Diagnostic dilation and curettage: is it used appropriately? British Medical Journal 306: 236–239, 1993

    Article  PubMed  CAS  Google Scholar 

  • Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. PharmacoEconomics 3: 354–361, 1993

    Article  PubMed  CAS  Google Scholar 

  • Dixon J, Welch HG. Priority selling: lessons from Oregon. Lancet 337: 891–894, 1991

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF. Resources allocation decisions in health care: a role for quality of life assessments? Journal of Chronic Disease 40: 605–616, 1987

    Article  CAS  Google Scholar 

  • Drummond MF. Cost-effectiveness guiddines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Economics 1: 85–92, 1992

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF. Economic analysis alongside controlled trials: an introduction for clinical researchers.Department of Health, Research and Development Division, London, 1993

    Google Scholar 

  • Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. International Journal of Technology Assessment in Health Care 7 (4): 561–573, 1991

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF, O’Brien B. Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes. Health Economics 2: 205–212, 1993

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF, Torrance G, Mason M. Cost-effectiveness league tables: more harm than good? Social Science and Medicine 37 (1): 33–40, 1993

    Article  PubMed  CAS  Google Scholar 

  • Eddy DM. Oregon’s methods: did cost-effectiveness analysis fail? Journal of the American Medical Association 266: 2135–2141, 1991

    Article  PubMed  CAS  Google Scholar 

  • Eddy DM. Medicine, money, and mathematics. Medical Audit News 3: 115–123, 1993

    Google Scholar 

  • Freemantle N, Watt I, Mason JM. Developments in the purchasing process in the NHS: towards an explicit politics of rationing? Public Administration 71: 535–548, 1993

    Article  Google Scholar 

  • Gafni A, Birch S. Guidelines for the adoption of new technologies: a presciption for uncontrolled growth in expenditures and how to avoid the problem. Canadian Medical Association Journal 148 (6): 913–917, 1993

    PubMed  CAS  Google Scholar 

  • Gerard K. Cost-utility in practice: a policy maker’s guide to the State of the art. Health Policy 21: 249–279, 1992

    Article  PubMed  CAS  Google Scholar 

  • Gerard K. Setting priorities in the new NHS: can purchasers use cost-utility information? Health Policy 25: 109–125, 1993

    Article  PubMed  CAS  Google Scholar 

  • Gerard K, Mooney G. QALY league tables: handle with care. Health Economics 2: 59–64, 1993

    Article  PubMed  CAS  Google Scholar 

  • Gudex C. QALYs and their use by the health service. Centre for Health Economics. Discussion Paper 20, University of York, York, 1986

    Google Scholar 

  • Kamlet S. The comparative benefits modelling project: framework for cost-utility analysis of government health care programs. US Department of Health and Human Services: Public Health Service, Washington, DC, 1992

    Google Scholar 

  • Kaplan RM. A Quality-of-life Approach to Health Resource Allocalion. In Strosberg MA, Weiner JM, Baker R, Fein IA (Eds). Rationing America’s medical care: the Oregon plan and beyond. Brookings Dialogues on Public Policy. The Brookings Institute, Washington, DC, 1992

    Google Scholar 

  • Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines ror using clinical and economic evaluations. Canadian Medieal Association Journal 146 (4): 473–481, 1992

    CAS  Google Scholar 

  • Lee JT, Sanchez LA. Interpretation of ‘cost-effective’ and soundness of economic evaluations in the pharmacy literature. American Journal of Hospital Pharmacy 48: 2622–2627, 1991

    PubMed  CAS  Google Scholar 

  • Mason JM, Drummond MF, Torrance GW. Some guidelines on the use of cost-effectiveness league tables. British Medical Journal 306: 570–572, 1993

    Article  PubMed  CAS  Google Scholar 

  • Maynard A. Developing the health care market Economic Journal 101: 1277–1286, 1991

    Google Scholar 

  • Michaels J. Cost effectiveness league tables. Correspondence. British Medical Journal 306: 1072, 1993

    CAS  Google Scholar 

  • Mooney GH. Economics, medicine and health care. Wheatsheaf Books Ltd., Harvester Press Publishing Group, Brighton, 1986

    Google Scholar 

  • Onratio Ministry of Health. Guidelines for the preparation of economic analysis to be included in submission to Drug Programs Branch for listing in the Ontario Drug Benefit Formulary/Comparative Drug Index. Ministry of Health, Toronto, 1991

  • Petrou S, Malek M, Davey PG. The reliability of cost-utility estimates in cost-per-QALY league tables. Pharmaco Econmics 3: 345–353, 1993

    Article  CAS  Google Scholar 

  • Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analysis in the medical literature: are methods being used correctly? Annals of Internal Medicine 116: 238–244, 1992

    PubMed  CAS  Google Scholar 

  • Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 296: 716–721, 1977

    Article  PubMed  CAS  Google Scholar 

  • Williams AH. Economics of coronary artery bypass grafting. British Medical Journal 291: 326–329, 1985

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Health Economics, University of York, Heslington, York, YO1 5DD, England

    James M. Mason

Authors
  1. James M. Mason
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mason, J.M. Cost-per-QALY League Tables. Pharmacoeconomics 5, 472–481 (1994). https://doi.org/10.2165/00019053-199405060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199405060-00004

Keywords

Search

Navigation